Back to Journals » International Journal of Nanomedicine » Volume 10 » Special Issue on diverse applications in Nano-Theranostics

Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics

Authors Bayarsaikhan E, Bayarsaikhan D, Lee J, Son M, Oh S, Moon J, Park H, Roshini A, Kim S, Song B, Jo S, Byun K, Lee B

Received 25 August 2015

Accepted for publication 17 December 2015

Published 23 August 2016 Volume 2015:10(Special Issue on diverse applications in Nano-Theranostics) Pages 281—292


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristian Vilos

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Thomas J Webster

Enkhjargal Bayarsaikhan,1,2,* Delger Bayarsaikhan,1,* Jaesuk Lee,1 Myeongjoo Son,1,3 Seyeon Oh,1 Jeongsik Moon,1 Hye-Jeong Park,1 Arivazhagan Roshini,1 Seung U Kim,4 Byoung-Joon Song,5 Seung-Mook Jo,6 Kyunghee Byun,1,3 Bonghee Lee1,3

1Center for Regenerative Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; 2Department of General Laboratory, National Cancer Center of Mongolia, Ulaanbaatar, Mongolia; 3Department of Anatomy and Cell Biology, Graduate School of Medicine, Gachon University, Incheon, Republic of Korea; 4Department of Medicine, University of British Columbia, Vancouver, Canada; 5Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA; 6Department of Emergency Medical Services, Eulji University, Seongnam-si, Gyeonggi-do, Republic of Korea

*These authors contributed equally to this work

Abstract: Advanced glycation end products (AGEs) are known to play an important role in the pathogenesis of neurodegenerative diseases, including Parkinson’s disease (PD), by inducing protein aggregation and cross-link, formation of Lewy body, and neuronal death. In this study, we observed that AGE-albumin, the most abundant AGE product in the human PD brain, is synthesized in activated microglial cells and accumulates in the extracellular space. AGE-albumin synthesis in human-activated microglial cells is distinctly inhibited by ascorbic acid and cytochalasin treatment. Accumulated AGE-albumin upregulates the receptor to AGE, leading to apoptosis of human primary dopamine (DA) neurons. In animal experiments, we observed reduced DA neuronal cell death by treatment with soluble receptor to AGE. Our study provides evidence that activated microglial cells are one of the main contributors in AGE-albumin accumulation, deleterious to DA neurons in human and animal PD brains. Finally, activated microglial AGE-albumin could be used as a diagnostic and therapeutic biomarker with high sensitivity for neurodegenerative disorders, including PD.

Keywords: theragnostic, microglia, AGE-albumin, neuronal death, receptor of AGE, Parkinson’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]